Celgene (CELG) Stock Research, Analysis & News
Quick Analysis on Celgene (CELG) Stock as of May 18, 2013
 | Previous Closing Price $123.48 is above 50 day moving average of $116.02 |
| Previous Closing Price $123.48 is above 200 day moving average of $93.76 |
 | The Price/Earnings To Growth ratio (PEG) is less than 1 |
 | The Stock pays no dividend |
| The closing price $123.48 is less than 8.70% away from its one year target price of $134.22 |
 | Current Short Ratio 1.30 is great than 1 |
(See more information about Celgene (CELG) Stock below)
Celgene (CELG) Stock Profile Summary
Celgene Corporation discovers, develops, and commercializes innovative therapies to treat cancer and immune-inflammatory diseases in the United States, Europe, and internationally. Its commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as patients with transfusion-dependent anemia; and THALOMID to treat, in combination with dexamethasone, patients with newly diagnosed multiple myeloma, as well as for the prevention and suppression of cutaneous manifestations of erythema nodosum leprosum recurrence. The company also sells VIDAZA, used to subtypes of myelodysplastic syndromes; RITALIN to treat attention deficit hyperactivity disorder; FOCALIN to prevent oncology-related disorders; and ALKERAN to treat multiple myeloma and carcinoma of the ovary. Its development stage products consist of CC-4047, which is in Phase I and Phase II clinical trials for treating disease indications, including sickle cell anemia, myelofibrosis, and multiple myeloma; CC-10004, a Phase II clinical trial product for psoriasis and psoriatic arthritis; CC-11050, a Phase I clinical trial completed product for inflammatory conditions; CC-401, a Phase I clinical trial completed product to identify kinases that regulate pathways critical in inflammation and oncology; CC-930, a Phase Ib clinicial trial completed product for fibrotic conditions; and Amrubicin, a Phase III clinical trial product for small cell lung cancer treatment. In addition, the company is researching stem cells derived from the human placenta, as well as from the umbilical cord. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. and Agios Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Celgene (CELG) Stock Key Statistics Research and Analysis as of May 18, 2013
| Stock Exchange | NasdaqNM |
| Market Capitalization | $52.103B
|
| Trade Volume (Average Trading Volume) | 4,122,228 (3,165,850) |
| Price/Sales | 9.04 |
| Price/Book | 9.29 |
| P/E | 37.57 |
| Earning/Share | $3.287 |
| Current Year EPS Estimate | $5.75 |
| Next Year EPS Estimate | $6.90 |
| Previous Closing Price | $123.48 |
| 50 Day Price Moving Average | $116.02 |
| 200 Day Price Moving Average | $93.76 |
| 1 yr Target Price | $134.22 |
| PEG Ratio | 0.96 |
| Short Ratio | 1.30 |
| EBITDA | $2.355B |
Celgene (CELG) Stock Competitor Research and Analysis
Mutual Funds with Celgene (CELG) Stock in its top 10 holdings
ETFs with Celgene (CELG) Stock in its top 10 holdings
Stock Research on Celgene (CELG)
Latest Market News on Celgene (CELG)
Click here to find the latest news on Celgene (CELG)
Looking for Market Opportunties?
Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center
Research on Celgene (CELG)
